A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients

NCT03145961 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]
[object Object]